Icosapent Ethyl

Introduction Overview

Generic Name

icosapent ethyl

Brand Name

Vascepa

Dosage Form

oral capsules

Drug Class

Miscellaneous antihyperlipidemic agents

Pharmacokinetics

Absorption:
Icosapent ethyl, the active moiety in Vascepa, is the ethyl ester of eicosapentaenoic acid (EPA), an omega-3 fatty acid. After oral administration, Vascepa undergoes hydrolysis by pancreatic lipases in the gastrointestinal tract to release EPA. This process allows the active fatty acid to be absorbed primarily in the small intestine. The absorption is enhanced when taken with food, facilitating bile salt secretion and micelle formation, which are important for lipid absorption. Clinical studies have demonstrated that intake with meals significantly increases plasma EPA concentrations compared to fasting administration, highlighting the clinical necessity for taking Vascepa with food.

Distribution:
Once absorbed, EPA is extensively incorporated into plasma phospholipids, lipoproteins, and cellular membranes, especially in cardiac and hepatic tissues. EPA has a high affinity for binding to plasma proteins, primarily albumin, facilitating systemic distribution. The volume of distribution reflects significant tissue uptake with prolonged incorporation into membrane phospholipids, thereby exerting therapeutic lipid-modifying effects. The distribution phase is characterized by slow equilibration with various tissues, contributing to its sustained pharmacodynamic actions.

Metabolism:
Icosapent ethyl is rapidly hydrolyzed to EPA, which then undergoes extensive metabolic processing primarily in the liver. The metabolic pathways include beta-oxidation in mitochondria and peroxisomes, converting EPA to various chain-shortened metabolites, some of which possess biological activity. Phase I and phase II hepatic enzymes also contribute to the metabolism, but EPA is not subject to significant cytochrome P450-mediated oxidative metabolism, which reduces the risk of drug-drug interactions. Research indicates that the metabolic fate of EPA involves incorporation into eicosanoid pathways modulating inflammation and lipid metabolism.

Elimination:
The elimination of EPA and its metabolites occurs predominantly via the renal route as metabolites and, to a lesser extent, via the fecal route. The elimination half-life of EPA is prolonged due to its incorporation into tissue lipids and slow release back into circulation. Steady-state plasma levels of EPA are reached within 4 weeks of consistent dosing. Clinical pharmacokinetic studies have shown that Vascepa’s elimination kinetics lend to sustained triglyceride lowering effects. The drug does not accumulate excessively, and dose adjustments based on renal or hepatic impairment have not been conclusively established but are generally not required.

Dosage Forms

Available Dosage Forms:
Vascepa is available exclusively as oral capsules containing 1 gram of icosapent ethyl in each soft gel. The capsules are gelatin-based and designed for oral administration with food to maximize bioavailability.

Dosages for Adults and Adolescents:
The standard adult dosing regimen for Vascepa is 2 grams administered orally twice daily (total 4 grams per day) with meals. This dosing schedule applies to both the treatment of severe hypertriglyceridemia (triglyceride levels ≥500 mg/dL) and adjunctive therapy to reduce cardiovascular risk in adults with elevated triglycerides (≥150 mg/dL) supplemented with maximally tolerated statin therapy.

Specific Patient Populations:
Vascepa is not approved for use in pediatric patients under 18 years of age. There are limited data concerning dosing adjustments in patients with hepatic or renal impairment; however, routine dose adjustments are not typically necessary. Caution is advised in patients with liver disease, bleeding disorders, or those who consume substantial quantities of alcohol. The pharmacokinetics and safety profile in pregnant or breastfeeding populations are not fully established; as such, Vascepa should be used only if the potential benefit justifies the potential risk to fetus or infant.

Mechanism Of Action

Vascepa's active component, icosapent ethyl, is a purified ethyl ester of eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid that exerts its therapeutic effect through multiple biochemical and cellular pathways. The primary mechanism is a reduction in hepatic triglyceride synthesis and secretion. EPA decreases the synthesis of triglyceride-rich very low-density lipoproteins (VLDL) in the liver by reducing the esterification of triglyceride fatty acids, resulting in lower plasma triglyceride concentrations.

At a molecular level, EPA modulates gene expression involved in lipid metabolism by activating peroxisome proliferator-activated receptors (PPARs), particularly PPAR-alpha, which enhances fatty acid beta-oxidation and decreases the synthesis of triglycerides. This activation leads to increased catabolism of triglyceride-rich lipoproteins and reduced synthesis of apolipoprotein C-III, a protein that inhibits lipoprotein lipase, thereby facilitating enhanced clearance of triglyceride-rich particles from plasma.

In addition to lipid-lowering effects, EPA exhibits anti-inflammatory properties by competing with arachidonic acid as a substrate for cyclooxygenase and lipoxygenase enzymes, leading to the production of anti-inflammatory eicosanoids and resolvins. These metabolites contribute to stabilization of atherosclerotic plaques and reduction in vascular inflammation, which are significant contributors to cardiovascular events.

Clinically, Vascepa's mechanism translates into the lowering of very low-density triglycerides without increasing low-density lipoprotein cholesterol (LDL-C), which differentiates it from other omega-3 fatty acid therapies containing docosahexaenoic acid (DHA) that may increase LDL-C. This lipid profile modulation has been linked with decreased incidence of major adverse cardiovascular events in patients with established cardiovascular disease or diabetes on statin therapy as demonstrated in large randomized clinical trials such as REDUCE-IT.

Pharmacological Actions

Reduction of serum triglyceride levels by decreasing hepatic VLDL triglyceride synthesis and secretion.
Activation of peroxisome proliferator-activated receptors (PPAR-alpha) enhancing fatty acid oxidation.
Increase in lipoprotein lipase activity resulting in enhanced clearance of triglyceride-rich lipoproteins.
Anti-inflammatory effects via modification of eicosanoid synthesis leading to reduced vascular inflammation.
Stabilization of atherosclerotic plaques through bioactive lipid mediator production.
Reduction of apolipoprotein C-III synthesis, diminishing lipoprotein lipase inhibition.
Improvement in lipid profiles without significant elevation of LDL cholesterol levels.
Modulation of hepatic lipid metabolism genes contributing to overall lipid lowering.
Enhancement of endothelial function and reduction of oxidative stress markers.
Potential anti-thrombotic effects due to alterations in platelet aggregation.
Adjunctive action with statins in cardiovascular risk mitigation via complementary mechanisms.

Therapeutic Or Clinical Uses

Adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (≥500 mg/dL).
Used concomitantly with maximally tolerated statin therapy to reduce the risk of myocardial infarction.
Reduction of stroke incidence in adults with elevated triglycerides and established cardiovascular disease.
Adjunctive therapy for unstable angina requiring hospitalization in adult patients with cardiovascular risk factors.
Management of elevated triglycerides in patients with diabetes mellitus and additional cardiovascular risk factors.
Part of comprehensive cardiovascular risk reduction programs including diet and lifestyle modifications.
Prevention of coronary revascularization in patients with elevated triglycerides on statin therapy.
Reduction in residual cardiovascular risk in patients with controlled LDL cholesterol but elevated triglycerides.

Side Or Adverse Effects

Muscle and joint pain (myalgia and arthralgia) reported in some patients.
Constipation potentially due to gastrointestinal motility changes.
Peripheral edema manifesting as swelling of hands, legs, or feet.
Reports of gout potentially linked to purine metabolism alterations.
Cardiac arrhythmias including palpitations, chest pressure, and fluttering sensations.
Rare but serious hypersensitivity reactions such as hives, facial swelling, and difficulty breathing.
Increased risk of bleeding events, particularly in patients on concomitant anticoagulants or antiplatelet agents.
Potential exacerbation of atrial fibrillation or flutter as documented in clinical trials.
Mild gastrointestinal discomfort including nausea and burping.
Occasional reports of dizziness and light-headedness related to cardiac effects.
Possible elevation in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels.

Precautions

Evaluate liver function before and during therapy; use cautiously in patients with liver disease.
Monitor for bleeding symptoms, especially in patients on blood thinners or with bleeding disorders.
Patients with fish or shellfish allergies should avoid Vascepa due to potential allergic reactions.
Use with caution in diabetic patients given altered lipid metabolism and comorbidities.
Avoid usage during pregnancy unless clearly needed; discuss potential risks with healthcare provider.
Assess thyroid function in patients with thyroid disorders prior to initiation.
Ensure medication adherence and monitoring due to the necessity of concurrent diet and exercise regimens.
Regular lipid panels and blood tests recommended to monitor therapeutic response and safety.
Educate patients to take Vascepa with meals to enhance absorption and therapeutic effect.
Caution in elderly patients due to potential increased susceptibility to bleeding and arrhythmias.

Warnings

Do not use in patients with known hypersensitivity to icosapent or any components of the formulation.
May increase the risk of bleeding; caution in patients receiving anticoagulant or antiplatelet therapy.
Not established for use in pediatric patients under 18 years of age.
Use caution in patients with bleeding or blood clotting disorders.
Potential risk of atrial fibrillation or flutter; patients should report any palpitations or chest discomfort.
Safety and efficacy in pregnancy and breastfeeding have not been established; avoid use unless necessary.
Concomitant use with large quantities of alcohol may exacerbate liver toxicity.
Monitor closely for signs of hypersensitivity reactions including anaphylaxis.
Risk of muddled cardiovascular risk reduction if dietary and exercise recommendations are not followed.
Discontinue use and seek emergency care if signs of severe allergic reaction occur.

Contraindication

Known hypersensitivity to icosapent ethyl or any other component of Vascepa capsules.
Patients with active bleeding or significant bleeding disorders should avoid use.
Not indicated in patients under 18 years of age due to lack of safety and efficacy data.
Caution advised but not contraindicated in severe hepatic impairment without close monitoring.

Drug Interactions

Increased bleeding risk when used concomitantly with anticoagulants such as warfarin, Coumadin, or Jantoven.
Potential additive effects on bleeding when combined with antiplatelet drugs like aspirin or clopidogrel.
Concomitant use with nonsteroidal anti-inflammatory drugs (NSAIDs) may further increase bleeding risk.
Herbal supplements with anticoagulant properties such as feverfew, ginkgo, garlic, and ginseng could potentiate bleeding.
Limited interaction with cytochrome P450 metabolic pathway drugs as EPA metabolism is non-CYP dependent.
Minimal interactions noted with commonly prescribed statins; however, close lipid monitoring advised.
Caution advised with drugs affecting triglyceride metabolism to prevent additive adverse effects.
No significant interactions documented with most antihypertensives or diabetic medications.
Monitoring advised when used alongside medications altering platelet function or coagulation.
Drug interaction profiles may alter in patients with hepatic or renal impairment.

Preparations Of The Drug

Oral capsule formulation containing 1 gram of icosapent ethyl per soft gel check.
Soft gel capsules designed for easy oral ingestion with food to improve drug absorption.
Available only by prescription; not available over-the-counter or as generic preparations.
Supplied in bottles typically containing 60 or 120 capsules for daily twice dosing regimens.
Formulated as a purified EPA ethyl ester with minimal DHA content to selectively reduce triglycerides without raising LDL cholesterol.
Manufactured to high pharmaceutical standards to ensure consistent potency and purity.
Stability profiles indicate storage at room temperature away from moisture and heat is optimal.
No currently available intravenous or alternative route formulations.
Packaging includes safety features to prevent accidental ingestion especially in pediatric populations.
Complementary to dietary and exercise treatment programs for lipid management.